Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CDK4 | P11802 | 1/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CCND1 | P24385 | 1/20 | 0.61 |
| ▸ | CDK7 | P50613 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
| ▸ | CCNH | P51946 | 1/20 | 0.61 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.61 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GLS | O94925 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484289 | 0.93 | CDK2 (0.67) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5477005 | 0.91 | CCNE1 (0.73) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5477822 | 0.89 | CDK2 (0.65) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5726612 | 0.87 | CDK2 (0.65) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5835581 | 0.85 | CDK2 (0.71) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5478304 | 0.84 | CDK2 (0.59) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5835927 | 0.83 | CDK2 (0.77) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5478261 | 0.82 | CDK2 (0.65) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5481269 | 0.82 | CCNE1 (0.64) | CDK2CCNE1CDK5ALDH1A1CCNT1 | |
| SCHEMBL5480558 | 0.82 | CDK2 (0.73) | CDK2CCNE1CDK5ALDH1A1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204649-B1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-10-17 | — | — | EP | claimed |
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA ITALIS S.P.A. (IT) | 2005-01-06 | — | — | US | claimed |
| US-6784198-B1 | 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-31 | — | — | US | claimed |
| EP-1204649-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-15 | — | — | EP | claimed |
| WO-2001014353-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA, S.P.A. (IT) | 2001-03-01 | — | — | WO | claimed |
| US-6114365-A | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-09-05 | — | — | US | claimed |
| EP-1204649-B1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-10-17 | — | — | EP | disclosed |
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA ITALIS S.P.A. (IT) | 2005-01-06 | — | — | US | disclosed |
| US-6784198-B1 | 2-(ARYLMETHYL-CARBONYLAMINO)-1,3-THIAZOLE DERIVATIVES; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-31 | — | — | US | disclosed |
| EP-1204649-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001014353-A1 | ARYLMETHYL-CARBONYLAMINO-THIAZOLE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA, S.P.A. (IT) | 2001-03-01 | — | — | WO | disclosed |
| US-6114365-A | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004120-A1 | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | CCAR2, BCL2, ROS1 | CDK2 26/4885CCNE1 513/4885CDK5 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.